Clinical Trial

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-17.
Status change: Not Yet Recruiting → Recruiting 2025-12-24
Trial Details
NCT Number NCT07138196
Lead Sponsor Qurient Co., Ltd.
Conditions Chronic Graft-Versus-Host Disease
Enrollment 18 participants
Start Date 2025-12-23
Primary Completion 2029-10-23 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-30